SCHOTT Pharma, a pioneer in drug containment solutions and delivery systems, has introduced the first 5.5 ml pre-fillable staked-needle glass syringe to the market. As part of the company’s syriQ BioPure® platform, this new large-volume syringe facilitates the shift towards large-volume drug delivery devices for biologic therapies administered at home. It is particularly essential for treatments in areas such as immunology, oncology and central nervous system disorders.
“This portfolio expansion marks a significant step for SCHOTT Pharma in advancing the trend of self-administering substantial drug doses subcutaneously at home,” said Andreas Reisse, CEO of SCHOTT Pharma. “With device-compatible large-volume options across all our product ranges and collaborations with leading device manufacturers, we provide pharma companies with solutions to efficiently scale home-care offerings and expedite their market entry.”
SCHOTT Pharma will present its full portfolio of large-volume drug containment and delivery solutions from October 28 to 30 at the CPHI Frankfurt trade-show in Frankfurt am Main, Germany.